Dyne Medical Group Leads Global Medical Device Market with Disposable Flexible Ureteroscope “URUS”
March 4, 2026 – Reporter: Jongbeom Choi
Dyne Medical Group Co., a specialized medical device company led by CEO Sung-hoon Lee, is accelerating its expansion in the global market with the innovative competitiveness of its disposable flexible ureteroscope, URUS.
URUS, the company’s flagship product, is a single-use flexible ureteroscope designed to fundamentally eliminate the risk of cross-infection, a persistent issue associated with conventional reusable endoscopes. Because the device does not require additional cleaning or sterilization processes, it can significantly reduce maintenance and operating costs.
A key differentiating feature of URUS lies in its working channel design. Conventional endoscopes typically place the working channel at the 3 o’clock or 9 o’clock position, which can create blind spots on either side when the scope is inserted into the patient. In contrast, URUS adopts a 6 o’clock working channel, enabling a clear field of view on both sides and improving procedural visibility.
Leveraging this product competitiveness, Dyne Medical Group has recently achieved notable international milestones. The company signed a KRW 100 billion supply agreement with EMS (Electro Medical Systems), a Switzerland-based global leader in urinary stone treatment devices, demonstrating the global competitiveness of Korean medical technology. In addition, the company has signed a memorandum of understanding (MOU) with the National Urology Center of Uzbekistan, expanding its presence across Central Asia and other Asian markets.
The company is also actively working to strengthen its global brand recognition. Dyne Medical Group regularly participates in major international conferences, including the World Congress of Endourology & Uro-Technology (WCET), where it shares its technological expertise supported by clinical evidence.
The company has established a quality management system that complies with international standards, including ISO certification. It has also obtained approval from the U.S. Food and Drug Administration (FDA) and is leveraging this milestone to pursue additional certifications and build local networks for entry into the North American and emerging markets.
CEO Sung-hoon Lee stated, “Based on the unique technology and clinical data of URUS, we are strengthening cooperation with global partners. Through continuous R&D investment and aggressive marketing, we aim to grow into a global leader in the field of urology medical devices.”
Through continuous technological innovation, Dyne Medical Group plans to further solidify its position as a global medical device company and contribute to the advancement of urology worldwide.
Meanwhile, the company was also selected for the 2025 Scale-Up Support Program for Startups (Startup Leap Package) operated by Seowon University. The government-led program supports startups in their growth phase—typically between three and seven years after founding—by providing up to KRW 200 million in commercialization funding, along with specialized programs designed to help promising companies scale their businesses.
Dyne Medical Group Leads Global Medical Device Market with Disposable Flexible Ureteroscope “URUS”
March 4, 2026 – Reporter: Jongbeom Choi
Dyne Medical Group Co., a specialized medical device company led by CEO Sung-hoon Lee, is accelerating its expansion in the global market with the innovative competitiveness of its disposable flexible ureteroscope, URUS.
URUS, the company’s flagship product, is a single-use flexible ureteroscope designed to fundamentally eliminate the risk of cross-infection, a persistent issue associated with conventional reusable endoscopes. Because the device does not require additional cleaning or sterilization processes, it can significantly reduce maintenance and operating costs.
A key differentiating feature of URUS lies in its working channel design. Conventional endoscopes typically place the working channel at the 3 o’clock or 9 o’clock position, which can create blind spots on either side when the scope is inserted into the patient. In contrast, URUS adopts a 6 o’clock working channel, enabling a clear field of view on both sides and improving procedural visibility.
Leveraging this product competitiveness, Dyne Medical Group has recently achieved notable international milestones. The company signed a KRW 100 billion supply agreement with EMS (Electro Medical Systems), a Switzerland-based global leader in urinary stone treatment devices, demonstrating the global competitiveness of Korean medical technology. In addition, the company has signed a memorandum of understanding (MOU) with the National Urology Center of Uzbekistan, expanding its presence across Central Asia and other Asian markets.
The company is also actively working to strengthen its global brand recognition. Dyne Medical Group regularly participates in major international conferences, including the World Congress of Endourology & Uro-Technology (WCET), where it shares its technological expertise supported by clinical evidence.
The company has established a quality management system that complies with international standards, including ISO certification. It has also obtained approval from the U.S. Food and Drug Administration (FDA) and is leveraging this milestone to pursue additional certifications and build local networks for entry into the North American and emerging markets.
CEO Sung-hoon Lee stated, “Based on the unique technology and clinical data of URUS, we are strengthening cooperation with global partners. Through continuous R&D investment and aggressive marketing, we aim to grow into a global leader in the field of urology medical devices.”
Through continuous technological innovation, Dyne Medical Group plans to further solidify its position as a global medical device company and contribute to the advancement of urology worldwide.
Meanwhile, the company was also selected for the 2025 Scale-Up Support Program for Startups (Startup Leap Package) operated by Seowon University. The government-led program supports startups in their growth phase—typically between three and seven years after founding—by providing up to KRW 200 million in commercialization funding, along with specialized programs designed to help promising companies scale their businesses.